Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Change in Cash (2016 - 2025)

Historic Change in Cash for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to $71.1 million.

  • Myriad Genetics' Change in Cash rose 72674.42% to $71.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.0 million, marking a year-over-year increase of 8145.16%. This contributed to the annual value of -$29.0 million for FY2024, which is 13892.62% down from last year.
  • As of Q3 2025, Myriad Genetics' Change in Cash stood at $71.1 million, which was up 72674.42% from -$17.3 million recorded in Q2 2025.
  • Myriad Genetics' Change in Cash's 5-year high stood at $176.8 million during Q3 2021, with a 5-year trough of -$93.2 million in Q1 2022.
  • Its 5-year average for Change in Cash is $2.0 million, with a median of -$4.4 million in 2024.
  • In the last 5 years, Myriad Genetics' Change in Cash plummeted by 96969.7% in 2024 and then soared by 72674.42% in 2025.
  • Myriad Genetics' Change in Cash (Quarter) stood at -$36.4 million in 2021, then decreased by 21.7% to -$44.3 million in 2022, then soared by 226.19% to $55.9 million in 2023, then tumbled by 96.24% to $2.1 million in 2024, then surged by 3285.71% to $71.1 million in 2025.
  • Its Change in Cash stands at $71.1 million for Q3 2025, versus -$17.3 million for Q2 2025 and -$10.9 million for Q1 2025.